Published in Toxicol Sci on September 30, 2014
Human bronchial epithelial BEAS-2B cells, an appropriate in vitro model to study heavy metals induced carcinogenesis. Toxicol Appl Pharmacol (2015) 0.79
Chronic inorganic arsenic exposure in vitro induces a cancer cell phenotype in human peripheral lung epithelial cells. Toxicol Appl Pharmacol (2015) 0.78
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. Oncotarget (2016) 0.77
Mitigation of arsenic-induced acquired cancer phenotype in prostate cancer stem cells by miR-143 restoration. Toxicol Appl Pharmacol (2015) 0.76
Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis. J Biol Chem (2016) 0.75
Oxidative stress, epigenetics, and cancer stem cells in arsenic carcinogenesis and prevention. Curr Pharmacol Rep (2016) 0.75
Arsenic in drinking water and prostate cancer in Illinois counties: An ecologic study. Environ Res (2016) 0.75
AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway. Oncol Lett (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
The hallmarks of cancer. Cell (2000) 113.05
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Cancer statistics, 2002. CA Cancer J Clin (2002) 10.79
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis (1997) 2.97
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.07
Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol (1996) 1.89
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res (2011) 1.82
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther (2011) 1.74
Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst (2002) 1.61
Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol (2005) 1.59
MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene (2012) 1.57
Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res (2005) 1.57
Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res (2012) 1.55
Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol (2007) 1.53
Inorganic arsenic and human prostate cancer. Environ Health Perspect (2008) 1.47
Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ Health Perspect (2010) 1.42
Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation (2005) 1.40
Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic Biol Med (2008) 1.39
Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog (2001) 1.35
Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A (2013) 1.26
Sodium arsenite administration via drinking water increases genome-wide and Ha-ras DNA hypomethylation in methyl-deficient C57BL/6J mice. Carcinogenesis (2002) 1.26
miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer (2013) 1.13
Infrequent RAS oncogene mutations in human prostate cancer. Prostate (1992) 1.10
Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. Oncogene (2005) 0.95
Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther (2008) 0.93
Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Pract Res Clin Endocrinol Metab (2013) 0.93
Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. Toxicol Sci (2014) 0.92
Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas. Mol Biol Rep (2011) 0.83
Matrix metalloproteinases-2,-3,-7,-9 and-10, but not MMP-11, are differentially expressed in normal, benign tumorigenic and malignant human keratinocyte cell lines. Biol Chem (2000) 0.81